Veradigm (MDRX) Stock Price, News & Analysis

Company Overview

Veradigm, Inc. (NASDAQ: MDRX) is a healthcare technology company that provides a comprehensive suite of clinical, financial and analytical solutions to medical practices, health systems and life sciences organizations. The company’s offerings are designed to streamline electronic health record (EHR) workflows, optimize revenue cycle management and improve patient engagement through integrated software modules and cloud-based platforms.

Veradigm’s product portfolio includes EHR and practice management systems tailored to ambulatory and specialty care settings, as well as revenue cycle management services that encompass billing, coding and claims processing. The company also delivers data-driven analytics and real-world evidence solutions that enable healthcare providers and researchers to derive insights from large clinical data sets, inform population health strategies and support clinical trial recruitment.

Headquartered in Chicago, Illinois, Veradigm primarily serves the United States market, supporting thousands of physician practices and healthcare facilities across all 50 states. The company maintains partnerships with major health systems, specialty societies and pharmaceutical firms, extending its reach into areas such as telehealth integration, patient outreach and post-acute care coordination. Veradigm’s cloud infrastructure is designed to meet industry security standards and facilitate interoperability with third-party health information exchanges.

Veradigm traces its roots to the clinical and financial solutions division of Allscripts Healthcare Solutions, which was rebranded and spun off in 2022 to focus exclusively on data-centric healthcare services. Led by an executive team with deep expertise in health information technology, the company continues to invest in platform enhancements, machine learning capabilities and strategic alliances aimed at advancing digital health initiatives and improving care delivery outcomes.

Key Stats

• Today's Range: $4.15 to $4.90
• 50-Day Range: $4.20 to $4.96
• 52-Week Range: $3.00 to $6.00
• Volume: 9,641 shs
• Average Volume: 196,630 shs
• Market Capitalization: $571.90 million
• P/E Ratio: 23.25
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MDRX Stock Analysis - Frequently Asked Questions

How have MDRX shares performed this year?

Veradigm's stock was trading at $4.60 at the beginning of the year. Since then, MDRX shares have increased by 3.3% and is now trading at $4.75.

How were Veradigm's earnings last quarter?

Veradigm Inc. (NASDAQ:MDRX) released its quarterly earnings results on Thursday, November, 4th. The software maker reported $0.27 EPS for the quarter, beating the consensus estimate of $0.18 by $0.09. The company's revenue was down 8.2% on a year-over-year basis.

Does Veradigm have any subsidiaries?

Veradigm subsidiaries include these companies: ZappRx, HealthGrid, and Practice Fusion.

How do I buy shares of Veradigm?

Shares of MDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Veradigm own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Veradigm investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), GE Aerospace (GE) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 11/04/2021
• Today: 5/07/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Business Services
• Industry: Computer integrated systems design
• Sub-Industry: Health Care Technology
• Current Symbol: NASDAQ:MDRX
• CIK: 1124804
• Web: www.allscripts.com
• Phone: (800) 334-8534
• Fax: 313-322-9600
• Employees: 8,000
• Year Founded: 1986

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 23.25
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $1.53 billion
• Price / Sales: 0.37
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 120,400,000
• Free Float: 105,175,000
• Market Cap: $571.90 million
• Optionable: No Data
• Beta: 0.52